Compositions and methods for treating CNS disorders

Patent metadata

Field	Value
Publication number	US-11530237-B2
Application number	US-202016748117-A
Country	US
Kind code	B2
Filing date	Jan 21, 2020
Priority date	Oct 16, 2014
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

Described herein are neuroactive steroids of the Formula (I):or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

First claim

What is claimed is:

1. A compound of the formula

2. A pharmaceutically acceptable salt of a compound of the formula

3. A pharmaceutical composition comprising a compound of the formula

and
a pharmaceutically acceptable excipient.

4. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of the formula

and
a pharmaceutically acceptable excipient.

Assignees

• Sage Therapeutics Inc

Inventors

• Martinez Botella Gabriel
• Salituro Francesco G
• Robichaud Albert Jean
• Harrison Boyd L

Classifications

• C07J13/007

  with double bond in position 17 (20) · CPC title

• C07J71/001

  Oxiranes · CPC title

• C07J5/0053

  not substituted in position 16 · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title